{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T11:58:23Z","timestamp":1793447903385,"version":"4.5.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100002732","name":"AOSpine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002732","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002617","name":"AORN Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002617","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004374","name":"Medtronic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004374","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019804","name":"Ulrich Medical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019804","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thespinejournalonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Spine Journal"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.spinee.2019.05.005","type":"journal-article","created":{"date-parts":[[2019,5,17]],"date-time":"2019-05-17T11:51:47Z","timestamp":1558093907000},"page":"1640-1647","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Longer follow-up continues to reveal no increased risk of cancer with the use of recombinant human bone morphogenetic protein in spine fusion"],"prefix":"10.1016","volume":"19","author":[{"given":"Joseph R.","family":"Dettori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens R.","family":"Chapman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John G.","family":"DeVine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"McGuire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark R.","family":"Junge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel C.","family":"Norvell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.spinee.2019.05.005_bib0001","doi-asserted-by":"crossref","first-page":"890","DOI":"10.7326\/0003-4819-158-12-201306180-00006","article-title":"Effectiveness and harms of recombinant human bone morphogenetic protein-2 in spine fusion: a systematic review and meta-analysis","volume":"158","author":"Fu","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.spinee.2019.05.005_bib0002","doi-asserted-by":"crossref","first-page":"877","DOI":"10.7326\/0003-4819-158-12-201306180-00005","article-title":"Safety and effectiveness of recombinant human bone morphogenetic protein-2 for spinal fusion: a meta-analysis of individual-participant data","volume":"158","author":"Simmonds","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.spinee.2019.05.005_bib0003","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.2106\/JBJS.15.01106","article-title":"Bone morphogenetic protein use and cancer risk among patients undergoing lumbar arthrodesis: a case-cohort study using the SEER-Medicare database","volume":"98","author":"Beachler","year":"2016","journal-title":"J Bone Joint Surg Am"},{"key":"10.1016\/j.spinee.2019.05.005_bib0004","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1097\/BRS.0b013e3182a3d3b4","article-title":"Risk of cancer after lumbar fusion surgery with recombinant human bone morphogenic protein-2 (rh-BMP-2)","volume":"38","author":"Cooper","year":"2013","journal-title":"Spine"},{"key":"10.1016\/j.spinee.2019.05.005_bib0005","doi-asserted-by":"crossref","first-page":"260","DOI":"10.14444\/50323","article-title":"Risk of cancer following lumbar fusion surgery with recombinant human bone morphogenic protein-2 (rhBMP-2): an analysis using a commercially insured patient population","volume":"12","author":"Cooper","year":"2018","journal-title":"Int J Spine Surg"},{"key":"10.1016\/j.spinee.2019.05.005_bib0006","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.2106\/JBJS.M.01190","article-title":"Cancer risk from bone morphogenetic protein exposure in spinal arthrodesis","volume":"96","author":"Kelly","year":"2014","journal-title":"J Bone Joint Surg Am"},{"key":"10.1016\/j.spinee.2019.05.005_bib0007","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1227\/NEU.0000000000000018","article-title":"Cancer after spinal fusion: the role of bone morphogenetic protein","volume":"73","author":"Lad","year":"2013","journal-title":"Neurosurgery"},{"key":"10.1016\/j.spinee.2019.05.005_bib0008","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/pds.2057","article-title":"Recombinant human bone morphogenetic protein-2 and pancreatic cancer: a retrospective cohort study","volume":"20","author":"Mines","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.spinee.2019.05.005_bib0009","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1097\/BRS.0000000000001671","article-title":"The risk of cancer with the use of recombinant human bone morphogenetic protein in spine fusion","volume":"41","author":"Dettori","year":"2016","journal-title":"Spine"},{"key":"10.1016\/j.spinee.2019.05.005_bib0010","unstructured":"Chapter 246-455 WAC hospital patient discharge information reporting [homepage on the Internet]. Washington State Legislature; 2007[updated May 18, 2007; cited November 20, 2014]. Available from: http:\/\/apps.leg.wa.gov\/WAC\/default.aspx?cite=246-455. Accessed May 7, 2019."},{"key":"10.1016\/j.spinee.2019.05.005_bib0011","unstructured":"Who must report. WAC, chapter 246-102, title 246 section 246-102-020. Available from:https:\/\/app.leg.wa.gov\/wac\/default.aspx?cite=246-102-020. Accessed March 7, 2019."},{"key":"10.1016\/j.spinee.2019.05.005_bib0012","unstructured":"American Cancer Society. Talcum powder and cancer. Available from:https:\/\/www.cancer.org\/cancer\/cancer-causes\/talcum-powder-and-cancer.html. Accessed May 7, 2019."},{"key":"10.1016\/j.spinee.2019.05.005_bib0013","unstructured":"Food and Drug Administration. Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). Available from:https:\/\/www.fda.gov\/medical-devices\/breast-implants\/breast-implant-associated-anaplastic-large-cell-lymphoma-bia-alcl. Accessed May 7, 2019."},{"key":"10.1016\/j.spinee.2019.05.005_bib0014","unstructured":"Gitelis S, Wilkins R, Yasko A. American Academy of Orthopaedic Surgeons. BMPs and cancer: is the risk real?2008. Available from:https:\/\/www.aaos.org\/AAOSNow\/2008\/May\/research\/research7\/?ssopc=1. Accessed May 7, 2019."},{"key":"10.1016\/j.spinee.2019.05.005_bib0015","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1002\/cncr.23160","article-title":"The bone morphogenetic protein pathway is active in human colon adenomas and inactivated in colorectal cancer","volume":"112","author":"Kodach","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.spinee.2019.05.005_bib0016","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/cr.2008.302","article-title":"Signaling cross-talk between TGF-beta\/BMP and other pathways","volume":"19","author":"Guo","year":"2009","journal-title":"Cell Res"},{"key":"10.1016\/j.spinee.2019.05.005_bib0017","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.omto.2017.10.002","article-title":"The dual role of bone morphogenetic proteins in cancer","volume":"8","author":"Bach","year":"2018","journal-title":"Mol Ther Oncolytics"},{"key":"10.1016\/j.spinee.2019.05.005_bib0018","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/nrc2467","article-title":"Bone morphogenetic protein signalling in colorectal cancer","volume":"8","author":"Hardwick","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.spinee.2019.05.005_bib0019","unstructured":"Infuse bone graft; indications, safety, and warnings. Medtronic. Available from:http:\/\/www.medtronic.com\/us-en\/healthcare-professionals\/products\/spinal-orthopaedic\/bone-grafting\/infuse-bone-graft.html. Accessed November 12, 2018."},{"key":"10.1016\/j.spinee.2019.05.005_bib0020","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.spinee.2011.04.023","article-title":"A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned","volume":"11","author":"Carragee","year":"2011","journal-title":"Spine J"},{"key":"10.1016\/j.spinee.2019.05.005_bib0021","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.1016\/j.spinee.2014.05.010","article-title":"The use of bone morphogenetic protein in thoracolumbar spine procedures: analysis of the MarketScan longitudinal database","volume":"14","author":"Veeravagu","year":"2014","journal-title":"Spine J"},{"key":"10.1016\/j.spinee.2019.05.005_bib0022","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1055\/s-0031-1298616","article-title":"The use of rhBMP in spine surgery: is there a cancer risk?","volume":"3","author":"Devine","year":"2012","journal-title":"Evid Based Spine Care J"}],"container-title":["The Spine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152994301930186X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152994301930186X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:31:29Z","timestamp":1761514289000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152994301930186X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":22,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S152994301930186X"],"URL":"https:\/\/doi.org\/10.1016\/j.spinee.2019.05.005","relation":{},"ISSN":["1529-9430"],"issn-type":[{"value":"1529-9430","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Longer follow-up continues to reveal no increased risk of cancer with the use of recombinant human bone morphogenetic protein in spine fusion","name":"articletitle","label":"Article Title"},{"value":"The Spine Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.spinee.2019.05.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}